KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Cost of Revenue (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Cost of Revenue data on record, last reported at $137.8 million in Q4 2025.

  • For Q4 2025, Cost of Revenue fell 57.83% year-over-year to $137.8 million; the TTM value through Dec 2025 reached $959.9 million, down 8.75%, while the annual FY2025 figure was $959.9 million, 11.72% down from the prior year.
  • Cost of Revenue reached $137.8 million in Q4 2025 per REGN's latest filing, down from $281.0 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $326.8 million in Q4 2024 and bottomed at -$201.0 million in Q4 2022.
  • Average Cost of Revenue over 5 years is $201.1 million, with a median of $223.4 million recorded in 2023.
  • Peak YoY movement for Cost of Revenue: soared 228.66% in 2023, then plummeted 57.83% in 2025.
  • A 5-year view of Cost of Revenue shows it stood at $214.4 million in 2021, then plummeted by 193.75% to -$201.0 million in 2022, then skyrocketed by 228.66% to $258.6 million in 2023, then increased by 26.37% to $326.8 million in 2024, then tumbled by 57.83% to $137.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $137.8 million in Q4 2025, $281.0 million in Q3 2025, and $275.6 million in Q2 2025.